Form 4: 180 Life Sciences Director Ryan Smith Granted Significant Equity Compensation

180 Life Sciences Corp. Director Ryan Lewis Smith has been granted 109,541 restricted common stock shares and 255,000 non-qualified stock options as compensation for his services.

Summary

• Ryan Lewis Smith, a Director of 180 Life Sciences Corp. (ATNF), reported the acquisition of equity securities.
• On June 17, 2025, Mr. Smith was granted 109,541 shares of common stock.
• These common shares are restricted stock subject to time-based vesting, with half vesting on December 17, 2025, and the remaining half on June 17, 2026, contingent on his continued service.
• The restricted stock was issued under the Issuer's 2022 Equity Compensation Plan.
• Additionally, Mr. Smith was granted 255,000 non-qualified stock options on June 17, 2025, with an exercise price of $0.929 per share.
• These options also vest in two equal tranches: half on December 17, 2025, and the other half on June 17, 2026, subject to continued service.
• The options were issued under the Issuer's 2025 Option Incentive Plan, which requires stockholder approval; options cannot be exercised prior to approval and will be cancelled if approval is not obtained.
• Both the restricted stock and options were issued as consideration for services rendered and agreed to be rendered as a member of the Board of Directors.
• Following these transactions, Mr. Smith beneficially owns 174,541 shares of common stock directly and 255,000 derivative securities (options) directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a routine filing, the granting of equity compensation to a director generally aligns their interests with shareholders, which is a positive for corporate governance. The only minor negative is the contingency of stockholder approval for the options.

Positives

• The granting of equity compensation to a director aligns their interests with those of the shareholders, potentially incentivizing long-term performance and commitment.
• The compensation package reflects the company's commitment to attracting and retaining experienced board members.

Negatives

• The non-qualified stock options are subject to stockholder approval of the 2025 Option Incentive Plan, introducing a contingency that could lead to their cancellation if not approved.

Risks

• The 255,000 non-qualified stock options granted are contingent on stockholder approval of the 2025 Option Incentive Plan; if approval is not obtained, these options will be cancelled and cannot be exercised.

Future Outlook

The equity grants are subject to time-based vesting over the next year, contingent on the director's continued service, indicating an expectation of ongoing commitment and contribution to the company's board.

Management Comments

• The securities were issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.

Industry Context

The granting of equity compensation, including restricted stock and stock options, to directors is a common practice across industries, particularly in the biotechnology and life sciences sectors, to align the interests of board members with long-term shareholder value creation and to incentivize retention.

Corporate Governance

Related Party Transactions

• The acquisition of common stock and non-qualified stock options by Ryan Lewis Smith, a Director of 180 Life Sciences Corp., constitutes compensation for his services and is a transaction with a related party.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value creation, potentially leading to more focused decision-making aimed at long-term company performance.
• Employees: While not directly impacting employees, the use of equity compensation plans sets a precedent for how the company values and incentivizes key personnel, which could indirectly influence broader compensation strategies.

Next Steps

• Stockholder approval for the 2025 Option Incentive Plan is required for the granted options to become exercisable.
• The restricted stock and options will vest in two tranches on December 17, 2025, and June 17, 2026, subject to continued service.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Equity Compensation, Stock Options, Restricted Stock, Director Compensation, 180 Life Sciences Corp, ATNF, Corporate Governance, Beneficial Ownership